The Faculty of Pharmaceutical Sciences at University of British Columbia (UBC) has one full-time postdoctoral position available in the lab of Dr. Sarah Hedtrich. Expected start date is negotiable, although a start date as early as possible is considered favorable.
About the project:
- The research project aims for the establishment of an in-situ gene therapy using CRISPR-Cas as a new treatment option for severe monogenic skin diseases.
- Specific aim is the development of smart delivery strategies for CRISPR/Cas components to (diseased) human epithelia with focus on the skin. Secondly, CRISPR/Cas based gene editing strategies will be developed and optimised to correct autosomal recessive congenital ichthyosis (ARCI) causing mutations in human skin.
- Successful candidates will be expected to take the lead within these projects, to publish manuscripts as a first author, and to present their data at conferences and lab meetings.
Requirements:
- Applicants should have a strong background in gene editing using CRISPR-Cas, cell culture and biomolecular methods.
- Experience with primary cells, organ models and non- viral gene delivery are considered strong assets.
- Applicants should have a PhD in Biomedical Engineering, Pharmacology, Biochemistry, or a related field with relevant experience.
Applications:
Applications to be sent via email to sarah.hedtrich@ubc.ca including:
- CV
- Description of research experience
- Statement of research interests
- Names of three referees
—————–Quick Overview————- | |
Organization | University of British Columbia (UBC) |
Country | Canada |
Fellowship Level | Postdoctoral |
Subject areas | Biomedical Engineering, Pharmacology, Biochemistry |
Fellowship amount | Varies |
Eligibility | Open to all nationalities |
Deadline | 31 August 2019 |
———————————— |